High-dose Antioxidants for Central Serous Chorioretinopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

June 30, 2009

Conditions
Central Serous Chorioretinopathy
Interventions
DRUG

antioxidants tablets

vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.

Trial Locations (1)

90110

Department of Ophthalmology, Faculty of medicine, Prince of Songkla university, Hat Yai

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Alcon Research

INDUSTRY

lead

Prince of Songkla University

OTHER